Konferenzschrift | Kongress
Emerging strategies for the management of hepatocellular carcinoma : [in Kyoto on June 7 - 8, 2014]
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISBN
-
9783318028157
3318028150
- Maße
-
28 cm
- Umfang
-
S. 654 - 801, VI S.
- Sprache
-
Englisch
- Anmerkungen
-
Ill., graph. Darst.
Literaturangaben
- Erschienen in
-
Digestive diseases ; Vol. 32, No. 6
- Schlagwort
-
Leberzellkrebs
Krebs
Onkologie
Leber
Gallenwege
- Ereignis
-
Veröffentlichung
- (wo)
-
Basel, Freiburg, Br., Paris, London, New York, NY, Chennai, New Delhi, Bangkok, Beijing, Shanghai, Tokyo, Kuala Lumpur, Singapore, Sydney
- (wer)
-
Karger
- (wann)
-
2014
- Beteiligte Personen und Organisationen
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 14:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Konferenzschrift
- Kongress
Beteiligte
- Kudo, Masatoshi
- International Kyoto Liver Cancer Symposium (4. : 2014 : Kyōto)
- Karger
Entstanden
- 2014
Ähnliche Objekte (12)
Liver cancer in Japan - state of the art : top articles of the 50th Annual Meeting of the Liver Cancer Study Group of Japan, June 5 - 6, 2014, Kyoto, Japan
Hepatocellular carcinoma 2009 and beyond : 25 tables
Viral hepatitis A to E : an update in 2010 ; 14 tables
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
Management of hepatocellular carcinoma: from prevention to molecular targeted therapy : 35 tables
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Liver cancer in Japan - state of the art : top articles of the 50th Annual Meeting of the Liver Cancer Study Group of Japan, June 5 - 6, 2014, Kyoto, Japan
Hepatocellular carcinoma 2009 and beyond : 25 tables
Viral hepatitis A to E : an update in 2010 ; 14 tables
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
Management of hepatocellular carcinoma: from prevention to molecular targeted therapy : 35 tables
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Liver cancer in Japan - state of the art : top articles of the 50th Annual Meeting of the Liver Cancer Study Group of Japan, June 5 - 6, 2014, Kyoto, Japan
Hepatocellular carcinoma 2009 and beyond : 25 tables
Viral hepatitis A to E : an update in 2010 ; 14 tables
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
Management of hepatocellular carcinoma: from prevention to molecular targeted therapy : 35 tables